Évaluation du cyclophosphamide au cours de la neuro-sarcoïdose : étude rétrospective chez 32 patients
暂无分享，去创建一个
S. Mouly | O. Mangin | P. Cacoub | D. Sène | C. Chapelon-Abric | K. Champion | W. Bigot
[1] D. Dormont,et al. Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis , 2017, JAMA neurology.
[2] P. Cluzel,et al. Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors. , 2017, Archives of cardiovascular diseases.
[3] L. Biard,et al. Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. , 2015, Clinical and experimental rheumatology.
[4] E. Kerty,et al. Overnight Response to Infliximab in Neurosarcoidosis: A Case Report and Review of Infliximab Treatment Practice , 2014, Clinical neuropharmacology.
[5] G. Raghu,et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial , 2008, European Respiratory Journal.
[6] J. Mazur,et al. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. , 2003, Chest.
[7] J. Broderick,et al. Diagnosis and management of neurological sarcoidosis. , 1997, Archives of internal medicine.